Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy and safety of current therapy.

HIV is "like a time bomb," said James Riley, a microbiologist at University of Pennsylvania, US. Even now — decades after the virus was identified — and with antiretroviral drugs allowing us to ...

An HIV drug could stop one of the early changes in skin cancer cells that leads to them becoming resistant to treatment, according to a Cancer Research UK-funded study published in Cancer Cell today ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

Timothy Ray Brown, the first person to be cured of the virus HIV passed away in Palm Springs on Tuesday after a decade-long battle with Leukemia. He was 54. In 2007, Brown underwent a bone marrow ...

Godfrey Dzhivhuho has dedicated his career to understanding HIV and other infectious diseases, inspired by the epidemic he witnessed growing up. Raised in Warrenton-Kimberly, South Africa, the oldest ...

Review of current evidence indicates immune checkpoint inhibitors offer comparable efficacy and safety for NSCLC in people living with HIV, with no adverse impact on viral load or CD4 counts.

LONDON, Sept 30 (Reuters) - Timothy Ray Brown, the first person known to be cured of HIV when he had a unique type of bone marrow transplant, has died in California after relapsing with cancer, his ...

ICIs are safe and effective for HIV-positive NSCLC patients, with no significant differences in survival outcomes compared to HIV-negative patients. The efficacy of immune checkpoint inhibitors was ...